• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Overview of Lean MASH and MASLD.

作者信息

Wong Vincent

机构信息

Mok Hing Yiu Professor of Medicine Department of Medicine and Therapeutics Faculty of Medicine The Chinese University of Hong Kong Hong Kong, China.

出版信息

Gastroenterol Hepatol (N Y). 2024 Dec;20(12):745-747.

PMID:39886000
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11776001/
Abstract
摘要

相似文献

1
Overview of Lean MASH and MASLD.精益MASH和MASLD概述。
Gastroenterol Hepatol (N Y). 2024 Dec;20(12):745-747.
2
Proton density fat fraction for diagnosis of metabolic dysfunction-associated steatotic liver disease.用于诊断代谢功能障碍相关脂肪性肝病的质子密度脂肪分数
Hepatology. 2025 Mar 25. doi: 10.1097/HEP.0000000000001318.
3
Single-cell landscape of peripheral immune cells in MASLD/MASH.代谢相关脂肪性肝病/非酒精性脂肪性肝炎中外周免疫细胞的单细胞图谱
Hepatol Commun. 2025 Apr 21;9(5). doi: 10.1097/HC9.0000000000000643. eCollection 2025 May 1.
4
Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases.代谢功能障碍相关脂肪性肝病（MASLD）和代谢功能障碍相关脂肪性肝炎（MASH）对心脏、肌肉和肾脏相关疾病的全身影响。
Front Cell Dev Biol. 2024 Jul 16;12:1433857. doi: 10.3389/fcell.2024.1433857. eCollection 2024.
5
Innovative approaches to metabolic dysfunction-associated steatohepatitis diagnosis and stratification.代谢功能障碍相关脂肪性肝炎诊断与分层的创新方法
Noncoding RNA Res. 2024 Oct 11;10:206-222. doi: 10.1016/j.ncrna.2024.10.002. eCollection 2025 Feb.
6
ACMSD inhibition corrects fibrosis, inflammation, and DNA damage in MASLD/MASH.ACMSD抑制可纠正代谢相关脂肪性肝病/非酒精性脂肪性肝炎中的纤维化、炎症和DNA损伤。
J Hepatol. 2025 Feb;82(2):174-188. doi: 10.1016/j.jhep.2024.08.009. Epub 2024 Aug 22.
7
Improvement of MASLD and MASH by suppression of hepatic N-acetyltransferase 10.通过抑制肝 N-乙酰基转移酶 10 改善 MASLD 和 MASH。
Mol Metab. 2024 Nov;89:102030. doi: 10.1016/j.molmet.2024.102030. Epub 2024 Sep 16.
8
BRUCE liver-deficiency potentiates MASLD/MASH in PTEN liver-deficient background by impairment of mitochondrial metabolism in hepatocytes and activation of STAT3 signaling in hepatic stellate cells.BRUCE肝脏缺乏通过损害肝细胞中的线粒体代谢和激活肝星状细胞中的STAT3信号通路，在PTEN肝脏缺乏背景下增强了代谢相关脂肪性肝病/非酒精性脂肪性肝炎。
bioRxiv. 2024 Sep 14:2024.09.13.611500. doi: 10.1101/2024.09.13.611500.
9
The potential role of omentin-1 in obesity-related metabolic dysfunction-associated steatotic liver disease: evidence from translational studies.网膜素-1 在肥胖相关代谢功能障碍相关脂肪性肝病中的潜在作用：来自转化研究的证据。
J Transl Med. 2023 Dec 11;21(1):906. doi: 10.1186/s12967-023-04770-8.
10
Clinical and Economic Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in a Spanish Mediterranean Region: A Population-Based Study.西班牙地中海地区代谢功能障碍相关脂肪性肝病（MASLD）的临床和经济负担：一项基于人群的研究
J Clin Med. 2025 Apr 3;14(7):2441. doi: 10.3390/jcm14072441.

本文引用的文献

1
What Is New in Metabolic Dysfunction-Associated Steatotic Liver Disease in Lean Individuals: From Bench to Bedside.瘦人代谢功能障碍相关脂肪性肝病的新进展：从 bench 到 bedside。 （注：“bench”和“bedside”在这里可能是比喻从基础研究到临床应用的过程，直译为“从实验台到病床边”，但这样表述稍显生硬，所以整体保留英文更符合语境。）
J Clin Med. 2024 Jan 3;13(1):278. doi: 10.3390/jcm13010278.
2
Higher mortality among lean patients with non-alcoholic fatty liver disease despite fewer metabolic comorbidities.非酒精性脂肪性肝病消瘦患者的死亡率较高，尽管合并代谢性合并症较少。
Aliment Pharmacol Ther. 2023 May;57(9):1014-1027. doi: 10.1111/apt.17424. Epub 2023 Feb 23.
3
Mortality and Liver-Related Events in Lean Versus Non-Lean Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis.瘦型非酒精性脂肪性肝病与非瘦型非酒精性脂肪性肝病患者的死亡率和肝脏相关事件：系统评价和荟萃分析。
Clin Gastroenterol Hepatol. 2023 Sep;21(10):2496-2507.e5. doi: 10.1016/j.cgh.2022.11.019. Epub 2022 Nov 26.
4
Association of genetic variations with NAFLD in lean individuals.瘦人非酒精性脂肪性肝病相关的遗传变异。
Liver Int. 2022 Jan;42(1):149-160. doi: 10.1111/liv.15078. Epub 2021 Oct 12.
5
Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach?非酒精性脂肪性肝病的白种瘦体型受试者与非瘦体型受试者具有相似的长期预后：是否需要重新评估 BMI 驱动方法？
Gut. 2022 Feb;71(2):382-390. doi: 10.1136/gutjnl-2020-322564. Epub 2021 Feb 4.
6
Performance of Simple Fibrosis Scores in Nonobese Patients With Nonalcoholic Fatty Liver Disease.非肥胖非酒精性脂肪性肝病患者中简单纤维化评分的表现。
Clin Gastroenterol Hepatol. 2020 Nov;18(12):2843-2845.e2. doi: 10.1016/j.cgh.2019.09.027. Epub 2019 Sep 28.
7
Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease.生活方式干预对非肥胖非酒精性脂肪性肝病患者的有益影响。
J Hepatol. 2018 Dec;69(6):1349-1356. doi: 10.1016/j.jhep.2018.08.011. Epub 2018 Aug 22.
8
Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients.非肥胖患者非酒精性脂肪性肝病的组织学严重程度与临床结局。
Hepatology. 2017 Jan;65(1):54-64. doi: 10.1002/hep.28697. Epub 2016 Jul 25.